Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Non Operating Income (2016 - 2021)

GT Biopharma (GTBP) has disclosed Non Operating Income for 12 consecutive years, with $156000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Non Operating Income fell 96.19% to $156000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$498000.0, a 102.31% decrease, with the full-year FY2025 number at $156000.0, down 87.02% from a year prior.
  • Non Operating Income was $156000.0 for Q4 2021 at GT Biopharma, down from $501000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $44.6 million in Q4 2019 to a low of -$228.5 million in Q3 2018.
  • A 5-year average of -$10.4 million and a median of -$467000.0 in 2019 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 527.09% in 2017, then tumbled 4964.07% in 2018.
  • GT Biopharma's Non Operating Income stood at $4.7 million in 2017, then crashed by 4964.07% to -$228.5 million in 2018, then surged by 119.51% to $44.6 million in 2019, then plummeted by 90.8% to $4.1 million in 2020, then crashed by 96.19% to $156000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Non Operating Income are $156000.0 (Q4 2021), $501000.0 (Q3 2021), and -$480000.0 (Q2 2021).